1. Home
  2. CYTK vs GGB Comparison

CYTK vs GGB Comparison

Compare CYTK & GGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$69.27

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Logo Gerdau S.A.

GGB

Gerdau S.A.

HOLD

Current Price

$4.67

Market Cap

9.4B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
GGB
Founded
1997
1901
Country
United States
Brazil
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Steel/Iron Ore
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
10.4B
9.4B
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
CYTK
GGB
Price
$69.27
$4.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
19
2
Target Price
$89.26
$5.38
AVG Volume (30 Days)
1.7M
17.8M
Earning Date
05-05-2026
04-27-2026
Dividend Yield
N/A
2.30%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,368,000.00
N/A
Revenue This Year
$7.37
$4.59
Revenue Next Year
$310.19
$3.46
P/E Ratio
N/A
$13.89
Revenue Growth
N/A
N/A
52 Week Low
$31.99
$2.83
52 Week High
$80.20
$4.98

Technical Indicators

Market Signals
Indicator
CYTK
GGB
Relative Strength Index (RSI) 45.21 52.61
Support Level $59.07 $4.44
Resistance Level $70.69 $4.66
Average True Range (ATR) 2.87 0.13
MACD -1.15 -0.03
Stochastic Oscillator 25.26 46.13

Price Performance

Historical Comparison
CYTK
GGB

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About GGB Gerdau S.A.

Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutors, mechanical construction bars, and reinforced steel locks. The company's geographical segment includes Brazil Segment; North America Segment; South America Segment as well as Special Steel Operations. It derives the majority of its revenue from the Brazil Operations segment, which includes the long, flat and special steel operations and the iron ore operation located in Brazil and joint ventures and associated companies located in Brazil.

Share on Social Networks: